

11:05 - 11:20

## United Kingdom



#### Harriet Teare

Deputy Director of Partnerships, Medicines and Healthcare products Regulatory Agency (MHRA)







#### **Regulatory Update: MHRA, UK**

Harriet Teare, Deputy Director for Partnerships

28 March 2023

#### Overview

- A recap of where we are now
- Overview of the statutory instruments we expect to lay
- Transitional arrangements
- Post-market surveillance
- International Recognition Framework



#### Where are we now?

- Twelve month extension to the implementation of the future UK Medical Device Regulations
- We are updating the UK Medical Device Regulations 2002 (UK MDR 2002)- to reflect the areas covered within the government response to the public consultation
- We expect to lay statutory instruments in 2023, which will amend the standstill date in the current UK MDR 2002, lay the transitional arrangements and the new post-market surveillance requirements.

# CE UK



#### **Overview of Statutory Instruments (SIs)**

Statutory Instrument	Purpose
Transitional Arrangements ( <i>Expected to be laid Spring 2023</i> )	Intended to amend the end of the standstill date (30 Jun 2023) in the current UK Medical Device Regulations 2002 (UK MDR 2002) and introduce the transitional arrangements for CE marked devices
Post-market Surveillance (Expected to be laid Autumn 2023)	Bring into force the new post-market surveillance requirements for CE marked and UCKA devices as laid out in the government response to the public consultation
Future Medical Device Regulations ( <i>Expected to be laid 2024</i> )	The SI relating to the future regime will bring into force the wider medical device regulations as laid out in the government response to the public consultation



#### **Transitional Arrangements**

UKCA marked under current UK regulations	<ul> <li>Sooner of:</li> <li>3 years for general medical devices</li> <li>5 years for IVDs, or</li> <li>when certifications expire</li> </ul>
CE marked under EU directives	As above for UKCA marked devices
CE marked under EU regulations (EU MDR and EU IVDR)	Up to 5 years



#### **Post-Market Surveillance**

More stringent PMS requirements

Tighter timelines for reporting adverse incidents

Detail on what should be covered in a PMS plan/PMS systems

Requirements for health institutions

Requirements for custom-made devices

Details on what should be covered in trend reports/FSCA/PSURs etc



#### **International Recognition Framework**

#### UK Life Sciences Council Priority Areas:

- 1. International recognition
- 2. Routes for innovation
- 3. System capacity

International recognition proposals:

- Building on current product recognition routes from the EU, rapidly explore building a UK product regulation equivalence route for the approvals of medical devices to include other trusted jurisdictions.
- Explore greater flexibility over the requirements for physical UKCA markings on parts, instructions and labels before
  products can be marketed in the UK. Make greater use of registration and traceability mechanisms to ensure patient
  safety.
- The MHRA has already announced its intention to expand recognition for medicines, and create a new recognition framework by the end of 2023. Aim to align changes to the Medical Devices Legislation to the Medicines legislative timeline if possible.





### Thank you

Disclaimer

This document was produced by the International Medical Device Regulators Forum. There are no restrictions on the reproduction or use of this document; however, incorporation of this document, in part or in whole, into another document, or its translation into languages otherthan English, does not convey or represent an endorsement of any kind by the International Medical Device Regulators Forum.

Copyright 2021 by the International Medical Device Regulators Forum.